Tris Pharma recently announced results from a Phase 3 clinical trial for cebranopadol – a compound opioid and nociceptin/orphanin FQ peptide (NOP) receptor agonist – for the treatment of moderate to severe pain.
The trial compared cebranopadol to placebo for the management of moderate-to-severe acute pain following full abdominoplasty (tummy tuck) in around 300 patients. Cebranopado outperformed placebo on the main efficacy measure – the pain numerical rate scale (NRS) area under the curve from four through 48 hours – which gives a comprehensive view of postoperative pain.
It is theorized that the compound activation of mu opioid receptors and the NOP receptors can provide pain relief while simultaneously reducing opioid side effects. Trial results note that cebranopado has a safety profile comparable to placebo, with evidence from prior studies showing low drug likability and potential for fewer respiratory events.
The results of this trial and others have led Tris Pharma to soon file a new drug application with the FDA for cebranopado, meaning a new opioid pain medication could be on the market in the near future – one which claims to be safer than currently available opioids.
